Doximity Inc (DOCS) 2022 Q1 法說會逐字稿

Good day and thank you for standing by. Welcome to the Doximity Fiscal First Quarter 2022 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your first speaker today, Doximity Head of Investor Relations, Mr. Perry Gold. Please go ahead.

Thank you, operator. Hello and welcome to Doximity's Fiscal 2022 First Quarter Earnings Call. With me on the call today are Jeff Tangney, Co-Founder and CEO of Doximity; Dr. Nate Gross, Co-Founder and CSO; and Anna Bryson, our CFO. A complete disclosure of our results can be found in our press release issued earlier today as well as in our related Form 8-K, all of which are available on our website at investors.doximity.com. As a reminder, today's call is being recorded, and a replay will be available on our website.

As part of our comments today, we will be making forward-looking statements. These statements are based on management's current views, expectations and assumptions and are subject to various risks and uncertainties. Actual results may differ materially, and we disclaim any obligation to update any forward-looking statements or outlook.

Please refer to the risk factors in our S-1, which will be updated from time to time by our other reports and filings with the SEC, including our upcoming filing on Form 10-Q. We would like to specifically caution investors that our future performance will be hard to predict in the foreseeable future given the COVID-19 pandemic.

Our forward-looking statements are based on assumptions that we believe to be reasonable as of today's date, August 10, 2021. Of note, it is Doximity's policy to neither reiterate nor adjust the financial guidance provided on today's call unless it is also done through a public disclosure such as a press release or through the filing of a Form 8-K.

Today, we will discuss certain non-GAAP metrics that we believe aid in the understanding of our financial results. A historical reconciliation to comparable GAAP metrics can be found in today's earnings release. Finally, during the call, we may offer incremental metrics to provide greater insight into the dynamics of our business. These details may be onetime in nature, and we may or may not provide updates on those metrics in the future.

I would now like to turn the call over to our CEO and Co-Founder, Jeff Tangney.

Thanks, Perry, and thank you, everyone, for joining our first earnings call as a public company. We'll begin with a few highlights.

First, our top line. I'm pleased to report that we delivered $72.7 million in revenue for the first quarter of our fiscal 2022, an increase of 100% over the same quarter last year. This growth was fueled by our existing clients as our net revenue retention rate grew to 167% over the trailing 12 months. Medical marketing requires highly specialized information flows, and our clients are learning that our network is well built for that purpose.

Okay. Second, our bottom line was equally strong this quarter with an adjusted EBITDA margin of 43%. Our reference selling model and third-party ROI studies continue to allow us to both scale and price efficiently.

Third, our network continues to grow. As frontline physicians grapple with high case loads and outbreaks, we're proud that our productivity tools have been able to help. Our e-signature and fax products saw record usage this quarter, and we expanded our enterprise telehealth platform to an additional 24,000 U.S. physicians. We now serve over 30% of all U.S. physicians with our paid telehealth offering.

Okay. Those are the highlights. But since this is our first earnings call, I do want to take a minute to step back and provide some broader context on our business and market opportunity, and then I'll end with a couple of product spotlights from the quarter.

For the past decade, it's been our mission at Doximity to help physicians be more productive to provide the best care for their patients. Today, over 80% of all U.S. physicians use our platform. Our Investor Relations site has a short 5-minute video demo from my Co-Founder here, Dr. Nate Gross, if you'd like to see firsthand how we help doctors video call their patients, signing paperwork remotely and keep up with medical news.

Our interactive platform allows top hospitals and pharmaceutical companies, the best brands in medicine to connect efficiently with the right physicians about new treatments, clinical trials and patient referrals. We then measure our clients' return on investment or ROI using third-party claims and prescription data.

In 2020, U.S. health care spent just 28% of its advertising dollars on digital channels, per IDC. That's less than half of the 63% share other U.S. industries spent on digital over the same period, per eMarketer. So we believe health care is still underindexed on digital and in the early innings of a much-needed decade-long technological shift.

Hospital and pharmaceutical marketers are our largest clients, comprising over 80% of our revenue. They generally organize their marketing teams by brand or service line, each with its own budget and decision-maker.

Landing the first brand and a blue-chip client is usually the hardest for us, but then our land-and-expand sales motion takes hold in 2 ways. First, we use our ROI results to cross-sell the other dozen or so brands within the same client, for example, from vascular surgery to neurosurgery or from drug A to drug B. With a median ROI of 10:1 for pharmaceutical clients and 13:1 for hospitals, as noted in our S-1, we've had good success signing additional brands. In Q1, we grew our number of brands per existing client by 21% over the prior year.

Second, we upsell existing client brands and service lines by expanding their audiences and interactive modules. For example, we can add an appointment booking module for hospital referrals or the ability to request samples from a local pharmaceutical rep. In Q1, we grew our modules per existing client by 20% over the prior year. So our cross-sell versus upsell growth was roughly equal.

We're a founder-led, mission-driven team, and this isn't our first rodeo. Shari, my Co-Founder; Joe, our commercial head; and I all took our last medical app from my dorm room to IPO in 2011. The average tenure of my direct reports is 7 years at the company. We believe experience matters in the complex world of health tech, and we've each done our 10,000 hours on it many times over. So it's our life's work to build better technology for medicine, to care for those who care for us.

Okay. That's our overview. I'd like to turn now to our product spotlight. Last quarter, we deployed over 5,000 new features and fixes to our site. As a product-led company, I'd like to spotlight a couple for you now, Doximity Dialer and Residency Navigator.

Doximity Dialer is our cloud-based telehealth platform. We launched the product in response to the pandemic and have been selling it since last summer. As highlighted at the top of the call, we expanded our paid telehealth platform by 24,000 physician licenses last quarter and now serve over 30% of all U.S. physicians with it.

In terms of active users, we're proud we grew year-on-year to over 300,000 unique physicians, nurse practitioners and physician assistants who completed virtual visits with us in the quarter. We're favored among physicians for our ease of use and a leader in the influential class IT ratings for our ability to integrate easily and reduce patient no shows.

While our footprint of unique telehealth providers grew, our number of virtual visits per provider declined year-on-year due to the sharp spike in free usage we saw last year at the start of the pandemic before we added paywalls to our app. Interestingly, we have seen an uptick in daily visits per provider since July 4 likely due to the Delta variant. As a reminder, we charge for telehealth on a per user basis like Zoom, not on a per visit basis.

We also put dozens of telehealth features this quarter. Here's a sampling. First, we partnered with UpToDate, the leader in evidence-based clinical decision support, to make it easy for providers to send their patient educational materials and seamlessly look up clinical questions during a virtual visit.

Second, we added one-tap interpreter access to make it easy for physicians to add an interpreter or a family member if needed. Third, we added wall charts that doctors can show and annotate as they do in an in-person visit. We've licensed the library of anatomical images, but many doctors are adding and sharing their own images, too.

And last, we created a physician name card or badge that appears at the bottom of a patient screen, which includes the doctor's institutional logo, title and credentials. It looks a bit like what a television news anchor might have. And a survey of 1,000 patients founded improved physician quality ratings and helped patients remember the physician's name if follow-ups were needed.

As these new features demonstrate, we believe telehealth will develop its own set of unique clinical and privacy features. We'll continue to lean into R&D in this area as we build what we hope will be an industry-leading solution.

Okay. Now let's shift the spotlight to our Residency Navigator product. In short, we help graduating medical school students to decide which residency programs to apply to. It's a difficult choice as there are over 4,500 different residency programs in the U.S., each with its own unique strengths. It's a major life decision as well as it's a 3- to 5-year commitment to working 80 hours per week.

So building on the work we already do with U.S. News & World Report each year to rank our country's best hospitals, in 2014, we began gathering physician alumni reviews on residencies. Topics range from research mentors to case volumes to work-life balance.

In sum, over 100,000 unique physicians have rated their residency on our site. In addition to alumni reviews, prospective applicants can filter programs by case volumes, step scores or maps of alumni. Applicants can also peruse attending CVs to compare themselves for the interviews.

After listening to the 40% of physicians who marry other health care professionals per the AMA, we added a couple's match feature in Q1. It allows physician couples to each set their own specialty and clinical criteria and find paired residency matches within 10 to 50 miles of each other. It's seen a lot of use.

We've also added the ability to filter by cost of living, school quality and other family-friendly attributes as more graduates broaden their searches outside the major metros. We're proud to help over 90% of new doctors find their first job and to use our proprietary data sets and insights to help them begin their careers on Doximity.

Okay. I'd like to end by thanking my 749 Doximity teammates, who've worked so incredibly hard this past year. I believe there's no better work than building something meaningful with people you like. And with this team, I get to do that every day. So thank you.

And with that, I'll hand the call over to Anna Bryson to discuss our financial performance and our guidance. Anna?

Thanks, Jeff, and thanks to everyone on the call today. As we begin our journey as a public company, we are excited by our strong first quarter performance. Our unique combination of high growth, robust profitability and strong free cash flow is well reflected in our first quarter results. First quarter revenue was $72.7 million, up 100% year-over-year. This growth was entirely organic and largely driven by the continued successful execution of our land-and-expand strategy. Specifically, approximately 80% of our growth came from existing customers.

Our leading physician network, native and interactive suite of modules and attractive ROI has enabled us to become a foundational digital partner for our customers. This is well reflected by our first quarter net revenue retention rate of 167%. This metric is defined in our earnings release and reflects subscription-based trailing 12-month revenue growth within existing customers net of churn. As a reminder, our net revenue retention rate is directly correlated to our revenue growth rate and thus fluctuates with it.

Our first quarter results were also driven by the growth in the number of customers spending 6 figures or more on our platform. We ended the quarter with 224 customers contributing at least $100,000 in subscription-based revenue on a trailing 12-month basis, a 58% increase from the 142 customers we had in this cohort a year ago. This increase was fairly evenly split between existing customers that we upsold and customers who are new to our platform.

So we are encouraged by both our continued growth within the top pharmaceutical manufacturers and health systems as well as the growing breadth of companies marketing on our platform. Doximity's value proposition is clearly resonating with an increasingly broad audience of mid-tier and long-tail pharmaceutical manufacturers and health systems. And we are even seeing more traction in end markets like medical devices and diagnostics.

Turning to our profitability. We are focused on building a meaningful business of scale with not only sustainable growth but also attractive margins. As we continue down the income statement, please note that unless otherwise stated, all references to our expenses and operating results are on a non-GAAP basis and are reconciled to GAAP numbers in the earnings release.

Gross margin in the first quarter was 89% compared to 79% in the prior year period. This quarter, our gross margin reflected a more typical range relative to the first quarter of last year. In last year's first quarter, we had experienced a significant increase in third-party software and hosting costs for our newly rolled out telehealth solution but had not yet begun earning any revenue to offset those costs. As a comparison point, our gross margin last quarter was 88% and in the full fiscal year of 2020 was 87%.

Turning to our operating expenses. R&D expense in the first quarter was $12.3 million and represented approximately 17% of revenue compared to $9.8 million and 27% of revenue a year ago. While we are increasingly reaping the benefits of operating leverage as we scale, R&D remains a critical investment area for us. As a product-led software company with over 1/3 of our head count in R&D, we plan to continue to invest in the creation of new products that can both enhance our physician experience and generate new monetization avenues.

Sales and marketing expense in the first quarter was $18.1 million and represented approximately 25% of revenue compared to $12.7 million and 35% of revenue a year ago. This year-over-year spend increase was primarily due to standing up a new telehealth sales team and continued investment in our other commercial solutions. Even with this investment, our highly efficient vertical sales model has allowed us to achieve significant leverage year-over-year.

Additionally, from a member marketing perspective, we spent less than 1% of our revenue advertising our platform in the first quarter. This is due to the strong network effects that have organically driven our member growth to over 80% of all U.S. physicians, and we do not anticipate this to change in the future.

G&A expense in the first quarter was $4.3 million and represented approximately 6% of total revenue compared to $2.7 million and 7% of revenue a year ago. Our 61% growth in G&A was driven primarily by costs associated with expanding our team and functionalities to effectively operate as a public company.

Adjusted EBITDA for the first quarter was $31.2 million, and adjusted EBITDA margin was 43% compared to $3.9 million, an 11% margin in the first quarter last year. We generated free cash flow for the first quarter of $32.4 million compared to $7.6 million in the first quarter last year.

Turning to our balance sheet. We ended the first quarter with no debt and $726.5 million of cash, cash equivalents and marketable securities, which included net IPO proceeds of $548.5 million.

Looking ahead as a newly public company, we want to provide a financial outlook that is consistent with how we manage the business internally. As a result, we'll be providing revenue and adjusted EBITDA guidance for the next quarter and the full fiscal year.

For the second fiscal quarter of 2022, we expect revenue in the range of $73 million to $74 million, representing 63% growth at the midpoint. And we expect adjusted EBITDA in the range of $26.4 million to $27.4 million, representing a 37% adjusted EBITDA margin at the midpoint.

For the full fiscal year 2022, we expect revenue in the range of $296.5 million to $299.5 million, representing 44% growth at the midpoint. We expect adjusted EBITDA in the range of $106 million to $109 million, representing a 36% adjusted EBITDA margin at the midpoint.

Now I'll provide a few more comments on guidance. With regards to our revenue outlook, we saw a pull forward of demand over the last several quarters as our customers shifted their budget to digital channels at an accelerated pace during the pandemic. Going forward, as the pandemic eases, we expect our customers to increase their portion of digital spend at a more normalized growth rate.

Our margin outlook takes into account continued investment in R&D, some return to normalcy in sales and marketing as a result of more in-person client activities and conferences and higher G&A costs associated with being a public company. That said, we still believe we'll be able to drive meaningful leverage versus our 31% adjusted EBITDA margin in the full fiscal year 2021.

In conclusion, while we are not anticipating growth to remain at the same elevated levels we saw this past quarter, we do believe we are in the early innings of a large and growing market opportunity aided by a secular shift to digital. It's been our aim over the past decade to become a trusted digital partner for our customers, and we are excited about the role we will continue to play in this industry transformation. Most importantly, we are proud to be a physician-first company, and we look forward to continuing to provide value for our physicians, our customers and our shareholders.

With that, I will turn it over to the operator for questions.

(Operator Instructions) Our first question comes from the line of Stephanie Davis with SVB Leerink.

So I'm sure I won't be the last to say this, but I would like to be the first. Congratulations on a very strong quarter coming out of the gate.

My first question is about your TAM. There was a lot of comments about the market opportunity in the prepared remarks, but it also feels like you're only really looking at the pharma and provider business as you're talking about this market opportunity. So to that extent, have you ever looked at other end markets? And what other markets would you think of as the lowest-hanging fruit, be it med tech or even some digital health peers?

Thanks, Stephanie. Great to hear from you, and thanks for the kind words. So I'll start by saying we certainly do believe our largest opportunity remains the core markets that we address today. We're very underpenetrated into our $18.5 billion TAM. And we believe health care's shift to digital provides us a significant opportunity to capture more wallet share there.

Now that said, our network really certainly affords us a lot of optionality to expand into adjacent end markets. And for example, as I mentioned in my prepared remarks, we are encouraged by the traction we're seeing amongst medical device and diagnostic companies.

A proof point of our progress here is we actually signed our first 7-figure deal in this space last quarter. And we're excited about the opportunity we have to further leverage our existing modules in order to deepen our digital partnerships with these customers.

So if you had to size where that could be by end of the year, is it still at a single-digit percentage? Or could it become more meaningful as the end market grows?

Yes. By the end of the year, we'd still be at single-digit percentage of our revenue. But that said, we absolutely see opportunity here and we look to continue to keep in those digital relationships over time. But I don't want to oversell the opportunity. Once again, our core markets remain our largest opportunity.

Okay. Stay conservative. I like it. And a quick follow-up on the model. Obviously, there's been a lot of push-pull since you became public. There was a reopening, there's Delta variant, I'm still at home. What are you assuming just in terms of your COVID impact for the guidance? And just seeing as I'm calling from here as opposed to hims this week, could this also return to virtual conferences and maybe more digital spend as a result?

Yes. So firstly, with regards to the Delta variant, it's very difficult for anybody to predict what will happen over the next 6 to 12 months. Now with regards to our current guidance, as expected, we have seen some return to in-person marketing activities since vaccines are rolled out. And we believe that going forward, just as we're seeing in many other aspects of society, a return to normal for health care marketing is really an adoption of hybrid with a mix of digital and face-to-face.

And then also, I'll add, we believe that our customers have seen tremendous value utilizing digital strategies for the past year. And in this new hybrid model that I just mentioned, we think our customers will continue putting more emphasis on digital, but that shift will occur at a more normalized pace, which is what is reflected in our 44% top line guidance for the year.

Understood. Very helpful, and congrats again.

Thank you.

Your next question comes from the line of Ryan Daniels with William Blair.

Yes. I will add my congratulations on the very strong start to life as a public company. So my first question is just in regards to the record use of the platform both for workflow solutions and the number of providers you're seeing with your pay dollar offering. Does that give you more monetization opportunities because of the more active engagement with the provider base that you're seeing today?

Ryan, this is Jeff. Good to hear from you. And Stephanie, good to hear from you as well. I'm also not at hims this week. So I guess that's the sign of our new world. Yes, right, I -- you're right. we did see record usage this past quarter with our e-signature and our fax products. And also, our telehealth providers was up year-over-year.

So we really do think that the active telehealth providers is a good proxy for the most active doctors across our whole platform and for those who see the most patients who are in the specialties that typically represent the highest percent of prescribers and referrers. So they're the ones that our customers are most interested in reaching. So we do think that provides an overall lift across the rest of our business.

Okay. And given that, that's the case and given that you're now up to 30% of all doctors on the platform, is that informing or changing your product development or monetization efforts on a go-forward basis if you think about kind of the R&D spend and where you're going to dedicate that because of how active that user base is and kind of a novel product that's unique that you might be able to add incremental solutions to drive more value to your pharma clients in particular?

Well, I'll let Dr. Nate here speak to any of the kind of M&A and longer-term initiatives there. But yes, I will say that our growth as the paid telehealth platform and our leadership in the class rankings, we are leaning in heavy in terms of our research and development, and there are a lot of adjacencies as you might well imagine as we build out that telehealth platform. A lot of that, we think we're able to build organically. Some of it, we are also looking at inorganically. So with that, Nate?

Brian, this is Nate. I'll take that one. We see tremendous organic growth potential within our existing business lines both in terms of current white space and in favorable market trends such as the shift to digital. And as you might imagine, there are numerous and massive market adjacencies that we would have a competitive edge in answering, thanks to our network effect and deep relationship with doctors and the health care ecosystem at large.

For example, post-telehealth referrals. So assisting the referral flow after an outpatient visit is why hospitals have spent countless millions buying back brick-and-mortar clinics. And our platform has unique advantages in ensuring patients are referred to the right specialty care after a visit.

Your next question comes from the line of Scott Berg with Needham.

Echoing the congrats on the great quarter. I guess a couple here. I think you called out some -- I guess, not caution but conservatism on demand trends going forward, and I think we can all appreciate that. And how about we flip the script to your hiring solutions a little bit? Are you seeing maybe an uptick or an increase of demand or usage on that product as we start reopening at least at some trajectory because maybe physicians are more apt to make a change in this environment than what they were a year ago?

Yes. Scott, great question. So as things reopen, we are certainly seeing increased demand for our hiring solutions, particularly benefiting in the part-time physician staffing space from the backlog of elective surgeries that have started to resume once vaccines are rolled out. And we are absolutely excited by the momentum that we're seeing here.

Now that said, the growth we saw amongst our hiring solutions customers was still at a lower rate than our overall business growth of 100%. So it was not a meaningful reason behind our growth for this quarter. But going forward, we're certainly excited about the momentum we're seeing there.

Great. Helpful. And then I guess on a follow-up question. You mentioned record EBITDA growth in the quarter. Obviously -- or record EBITDA margins, I should say, at 43%, which are crazy good. How should we think about growth going forward? I think one of the questions I get most from investors is, "Hey, the growth rate is obviously really strong. The margins are probably even more impressive at the growth rate." Are there ways that you can maybe invest either faster or heavier just to see the motion -- the growth movement that you're seeing today?

Yes. So a couple of things here, Scott. So firstly, absolutely. We remain focused on continuing to invest in our platform to provide the best value for our physicians and our customers, and our guidance reflects that. You do see some compression to our EBITDA margins in the back half of the year really due to the fact that we are going to continue investing there.

More specifically, our margin outlook takes into account a more normalized revenue growth rate, continued investment in R&D and assumption of some return to in-person client activities and conferences for sales and marketing. In the same way we're assuming our clients will adopt a hybrid sales and marketing model, so are we. And then there's also naturally higher costs associated in G&A with being a public company. So we are absolutely continuing to invest there, and we'll certainly continue to invest in top line growth.

Excellent. Congrats on the quarter.

Next question comes from the line of Brian Peterson with Raymond James.

I'll echo my congratulations. It's amazing to talk about the rule of 40, but you guys are setting a new dynamic here at the Rule of 120. So just maybe one question for me, and it's kind of a follow-up to Scott's question. But if we had to think about the gating factors on growth, I think Jeff or Anna, I don't know who wants to take this, but what would those be? And what do you see as kind of the 2 kind of key levers to growth as we think about the next 3 to 5 years?

Brian, Jeff here. I'll take that one. And I do like the Rule of 140 line. I might crib that one from you. The short answer is that there aren't that many huge constraints on our growth. Again, we think we're in the early innings of a very, very large addressable market. Again, physicians on a day-to-day basis decide 14% of our GDP as a country, right? And being able to help connect that, educate that, provide the highly specialized information that they need to do their jobs well each day, we think, is a very large undertaking.

That all said, the health care industry only moves so fast. And so as we had pointed out in our top of the call comments, only 28% of health care advertising was digital in 2020. And that shift, it's moving a little slower than other industries, which have been 63% digitally in 2020. And of course, we have our own challenges in hiring great engineers and growing our product set and skills. But I'd say the biggest rate limiter is just how quickly health care moves to digital.

Your next question comes from the line of Jackson Ader from JPMorgan.

Jeff, can I just follow up on that shift to digital? Fully under-appreciating that 2020 and the Delta variant is kind of a onetime thing. But if we think about the shift to digital in a normal environment, what percent of the pie do you expect that will typically shift to digital each year?

I'm sorry. I was on mute there. Thanks, Jackson. Great question. Prior to COVID hitting, IDC and eMarketer and others have put out reports, seeing a few point shift each year to persist from pharma

(technical difficulty)

normal shift. It's maybe 5 points a year. I think this past year, we saw it grow a lot more than that as it should given that things were completely shut down for the year. Our forecast here, as we look out, is we do expect a return to that normalized shift of 5, 7 points a year moving to digital and health care.

Okay. All right. Great. And then I was worried for a second here that you weren't expecting any shift given the [silence], but the -- Anna, a quick question for you. Net revenue retention that accelerated over the -- I think what people thought was the possibly unsustainable 150% rate at the end of last quarter. So what should we be thinking about for the remainder of the year on that metric?

Thanks, Jackson. And I'll remember to unmute here. So net revenue retention going forward -- as Jeff mentioned, net revenue retention is a direct function of our revenue growth. So while we are not guiding to this metric, we do think that looking back at kind of pre-pandemic levels to looking at our fiscal 2019 and fiscal 2020, where we had net revenue retention in the range of 130% plus, it's probably more representative of what our go-forward will look like post pandemic, which is still a very robust net revenue retention rate, and we're incredibly happy with that.

Your next question comes from the line of Ricky Goldwasser from Morgan Stanley.

Yes. So I wanted to go back to your comment around sort of pull forward of demand. It seems that the guidance sort of implies second half growth sort of around 20-plus percent. As we think about sort of 2022 as sort of the base for '23, and I know it's early and you just guided for 2022, but how should we think about sort of that '22 as a base year, right? Is that sort of the growth rate that we should be factoring into 2023. If you can just talk a little bit about sort of that baseline and growth from there.

Yes, of course, Ricky. Great to hear from you. So while we certainly don't know what the dynamic will necessarily be in the future, we do believe that the rate at which budgets will shift to digital channels will be closer to what we're seeing pre-pandemic, if not slightly more pronounced, given the significant value that we believe our customers have realized utilizing these digital channels just like the last year. So once again, I would point back to what we're seeing pre-pandemic in our 2019, 2020 growth.

So around what -- that's like 125% upsell? Is that how we should be thinking about that?

From a net revenue retention rate, it was 130% plus for those 2 years.

Okay, great. That's helpful. And then just one follow-up question. When we think about the number of customers with more than $100,000 in revenue, it seems that you are way ahead on your goal for 2022. Can you just share with us what was total revenues from these customers of the overall mix?

Oh, sorry. I was on mute. They represented 88% of our total trailing 12-month revenue.

Your next question comes from the line of Sean Wieland from Piper Sandler.

What can you tell us about the telehealth segment, about the economics of this business, if you can put any numbers around it? And part 2 of the question is, how are you thinking about going after the enterprise market for more of an enterprise-level strategy to telemedicine?

Sean, Jeff here. Yes, so the telehealth market, I mean overall, it's still a very small percentage of our revenue. It went from 2% to maybe 3% or so this past quarter. We're doing very well in the enterprise side. In fact, most of that revenue is from the enterprise side.

So as we had stated out on the road show, we have over 150 different health systems who work with us. And that's really where most of our traction has been. So we're deep into doing the EHR integrations and other work to work with these larger health systems. We're also very popular among small practices, and we've done well there. But actually, the bigger numbers are from the enterprise side.

What's roughly the mix there between enterprise and individual subscriptions?

I don't know that off the top of my head, but I'd just say that the vast majority is enterprise.

Your next question comes from the line of Mike Ng with Goldman Sachs.

I just have 2. First, I just wanted to ask about optionality. Would you be able to share any progress that you're making against any new business development initiatives, whether that's investing more aggressively beyond physicians or targeting advertisers beyond the core base of pharma manufacturers and health systems?

Mike, sure. So we have been making, on the user side, strong growth within nurse practitioners and PAs. We have over half of nurse practitioners and PAs on the site. And we believe that will lead to some meaningful opportunities to continue to build out businesses that really matter for them in the future. As Anna already alluded to, we've had some success in the med device and diagnostics space this past quarter.

But what I really want to make sure I emphasize is that with even all of our business development, we are a product-led software company at -- trying to build a meaningful business at scale that will use both our partnerships and our healthy level of cash on the balance sheet to be able to move quickly and with confidence into building new products. And I think our telehealth expansion that we had into that industry is a great example of that.

As that landscape evolves, I think the size of our platform as well as the cash on the balance sheet might allow us to extend our speed and confidence to potentially extend BD beyond into making synergistic acquisitions. But those are more likely to be for talent or for product, less so for revenue because as I alluded to before, we see tremendous organic growth potential in our existing business lines.

Great. And second, would you be able to talk about any expected seasonality as it relates to the timing of marketing campaigns for the rest of the year or maybe in the quarter that may be worth calling out, if there's anything?

Yes. Thanks, Mike. So there's not any expected revenue seasonality. What we're experiencing is very quick program launches on our platform actually, which has contributed to quicker revenue conversion for us. This is a result of both our customers adopting these more robust and focused digital strategies as well as our investment in our customer success team as they've become really increasingly efficient at helping our customers quickly develop and launch their programs. So there isn't any expected seasonality going forward.

There are no further questions over the phone line at this time. I would now like to turn the call back to Mr. Jeff Tangney. Sir?

Well, thank you. I want to thank everyone for joining us today, and we look forward to talking to you all next quarter. Thanks so much.

This concludes today's conference call. Thank you for participating. You may now disconnect.